Share
.webp)
.webp)
.webp)
.webp)
Nick Smith
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has promoted Nick Smith to President and Chief Financial Officer.
In his expanded role, Smith will continue to lead Alto’s finance function while taking responsibility for corporate strategy and business development. He will report to Amit Etkin, M.D., Ph.D., Alto’s Founder, Chief Executive Officer, and Chair of the Board of Directors.
Smith joined Alto Neuroscience in 2021 as Chief Business Officer and has served as Chief Financial Officer since 2022. During his tenure, he has played a central role in the company’s corporate development, financial planning, and capital strategy.
His leadership has included supporting Alto’s initial public offering and subsequent financing activities aimed at advancing the company’s pipeline. Smith also led corporate development efforts surrounding Alto’s acquisition of ALTO-207 in May 2025 and the financings that followed to support the program’s development.
As President and Chief Financial Officer, Smith will continue to oversee Alto’s financial operations while contributing to broader strategic priorities, business development activities, and corporate growth initiatives. His expanded responsibilities reflect the company’s continued focus on advancing its precision-medicine approach to neuropsychiatric disorders.
Alto Neuroscience is developing novel therapies designed to address significant unmet needs in neuropsychiatric care through a precision-medicine strategy. The company’s approach aims to identify patient characteristics that can help guide treatment selection and improve therapeutic outcomes.
Smith’s combination of financial, corporate development, and strategic experience is expected to support Alto as it advances its development programs and pursues opportunities to strengthen its position in the biopharmaceutical sector.
